Skip to contentI
Immuneering Corp
I
IMRXImmuneering Corp Q2 2026 · 10-Q
Revenue—
Net Income-$17.27M-$17.27MN/M vs Q2 2025 EPS Diluted-$0.27-$0.27N/M vs Q2 2025 Operating Income-$19,000,408N/M Operating Cash Flowderived-$16,501,393N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immuneering Corp · CIK 1790340 · Engraved from SEC EDGAR
Free Cash Flowderived-$16,528,760N/M ended Jun 30, 2026 · filed Aug 5, 2026 · 36 d after period end